VKTX Jumps After Viking Shows Monthly and Every-Other-Week Shots Can Hold Most Weight Loss
Viking reported 16–19% weight loss at week 21 and strong maintenance on monthly dosing. GI side effects in the later phase looked like placebo.
Viking reported 16–19% weight loss at week 21 and strong maintenance on monthly dosing. GI side effects in the later phase looked like placebo.
Distant 2030 goals failed to ease concerns over patents and Lilly.
CHMP recommends FREHEMGO (denecimig) for haemophilia A, with or without inhibitors. Novo and Orbis will develop oral cardiometabolic drugs.
Ascendis will develop TransCon obesity and cardiometabolic programs itself after ending its Novo collaboration and starting a $400M buyback.
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.
Semaglutide still drives most of Novo Nordisk’s sales. Morgan Stanley and other banks warn the mid-2030s patent cliff and Eli Lilly competition look underpriced.